Synergistic effects of geldanamycin and antitumor drugs.
Yao Xue Xue Bao
; 36(8): 569-75, 2001 Aug.
Article
en En
| MEDLINE
| ID: mdl-12579931
AIM: To study the effect of geldanamycin (GDM) on cell-cycle of human hepatoma BEL-7402 cells and the antitumor activity of cisplatin and mitomycin C in combination with GDM in vitro and in vivo. METHODS: MTT assay was used to determine the growth inhibition of hepatoma BEL-7402 cells. Cell cycle was analyzed by flow cytometry. Transplantable murine hepatoma 22 model was used to evaluate the antitumor activity of drugs in vivo. RESULTS: The IC50 value of GDM for hepatoma BEL-7402 cells by MTT assay was found to be 0.28 mumol.L-1. At concentrations of 0.1, 1.0, and 10 mumol.L-1, GDM reduced the proportion of S phase and induced G2/M arrest in BEL-7402 cells. At relatively low cytotoxic concentration, 0.1 or 0.2 mumol.L-1, GDM markedly potentiated the cytotoxicity of a series of chemotherapeutic agents including cisplatin, mitomycin C, adriamycin and cytarabine against BEL-7402 cells. The inhibition of tumor growth by cisplatin and mitomycin C was also enhanced in transplantable hepatoma 22-bearing mice when these agents were administered in combination with GDM 0.38 mg.kg-1. The synergistic effects were very significant with CDI < 0.7. CONCLUSION: These results suggest that GDM, as a biochemical modulator targeting Hsp90 function, may be potentially useful in cancer chemotherapy.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Quinonas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Antibióticos Antineoplásicos
Límite:
Animals
Idioma:
En
Revista:
Yao Xue Xue Bao
Año:
2001
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
China